Anthera Pharmaceuticals (ANTH) 3.84 $ANTH
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 11:45AM CST
JIVE: 5.34 (+0.02), JONE: 10.18 (+0.18), FXEN: 1.99 (+0.10), CDTI: 2.35 (+0.11), SGMO: 15.40 (+0.14), EVRY: 1.00 (-0.04), INXN: 32.04 (+0.14), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), BLDP: 2.66 (-0.26), PNTR: 7.90 (+0.01), PRSS: 2.95 (-0.08), BXE: 2.79 (+0.05), ANTH: 3.84 (+0.06), PIR: 12.52 (+0.17), PSTR: 4.63 (+0.14), MKTO: 28.24 (+0.20), ANDE: 45.11 (+0.71), DGLY: 11.50 (-0.40), DCTH: 1.14 (+0.04)
Strength Seen in Anthera (ANTH): Stock Soars 25% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:25AM CST
Anthera (ANTH) was a big mover last session, with shares surging 25% on the day.
ANTH: 3.84 (+0.06), AFFX: 11.45 (+0.02)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HNNA: 24.40 (+0.40), OFED: 20.41 (+0.16), DLHC: 2.21 (-0.06), BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), BIOC: 1.41 (+0.22), NWFL: 30.00 (+0.25), ATOS: 1.67 (+0.11), SPDC: 1.18 (+0.05), FSC: 7.23 (+0.12), OVBC: 24.00 (unch), QTWW: 2.96 (-0.04), ANTH: 3.84 (+0.06), IMI: 1.70 (-0.20), FBMS: 14.69 (+0.31), EXA: 10.46 (+0.09), FNJN: 2.77 (-0.36)
Most active Nasdaq-traded stocks
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.86 (-0.22), MU: 31.85 (-0.09), FTR: 8.38 (+0.01), AMD: 3.15 (+0.03), ANTH: 3.84 (+0.06), ACHN: 10.89 (-0.20), ODP: 9.59 (-0.02), MSFT: 43.87 (+0.78), INTC: 34.36 (+0.23), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03)
Anthera Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
PR Newswire - Tue Feb 10, 2:56PM CST
Anthera Pharmaceuticals (NASDAQ: ANTH) today announced that the company has received formal notification from the Nasdaq Stock Market ("Nasdaq"
, indicating that the Company has regained compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,000,000 in stockholders' equity or maintaining a market value of $50,000,000 or greater for ten consecutive business days. Nasdaq has determined that Anthera has maintained market value of at least $50,000,000 for the last ten consecutive business days and as such, the Company has met alternative listing requirements for continued listing.
ANTH: 3.84 (+0.06)
Anthera Pharma spikes 30% on continuation of lupus study
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 10:41AM CST
ANTH: 3.84 (+0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus
PR Newswire - Tue Feb 10, 7:45AM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 study, evaluating the SRI-6 response at the 24 week time point. Enrollment in the trial is projected to conclude in mid-2015.
ANTH: 3.84 (+0.06)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
AYI: 163.40 (+0.78), BDC: 87.78 (+0.61), ANTH: 3.84 (+0.06), CB: 102.06 (+0.43), CGI: 25.30 (+0.05)
Anthera Pharmaceuticals names Klara A. Dickinson as SVP
M2 - Thu Jan 08, 4:54AM CST
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) disclosed on Wednesday the election of Klara A. Dickinson as senior vice president & chief regulatory officer.
ANTH: 3.84 (+0.06)
Anthera Pharmaceuticals Announces Appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer
PR Newswire - Wed Jan 07, 2:45PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced the appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer.
ANTH: 3.84 (+0.06)
Can the Uptrend Continue for Anthera Pharmaceuticals (ANTH)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 7:44AM CST
Can the Uptrend Continue for Anthera Pharmaceuticals (ANTH)?
ANTH: 3.84 (+0.06)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:35PM CST
CERS: 5.53 (+0.08), RICE: 19.13 (-0.22), ECR: 7.29 (+0.12), ANTH: 3.84 (+0.06), NERV: 4.68 (+0.09), AU: 12.33 (+0.36), JNUG: 30.90 (+1.14), WTI: 6.55 (+0.41), CYBX: 57.03 (+0.26), GST: 2.89 (unch)
Anthera jumps as interest in lupus med builds
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:36AM CST
ANTH: 3.84 (+0.06)
Anthera Pharmaceuticals Announces Lupus Symposium During 2015 JP Morgan Healthcare Conference
PR Newswire - Tue Dec 30, 1:30PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it is inviting its shareholders and investors to a symposium on Systemic Lupus Erythematosus (SLE) at 3:30 PM on Wednesday, January 14th at the Mystic Hotel in San Francisco, CA.
ANTH: 3.84 (+0.06)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jbcb9/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Boehringer Ingelheim - Amgen - GlaxoSmithKline - Merck & Co - Symphogen - Eisai - Rigel Pharmaceuticals - Immunomedics - HanAll Biopharma - PhytoHealth - Anthera Pharmaceuticals - SuppreMol - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/3jbcb9/idiopathic
IMMU: 3.84 (unch), ANTH: 3.84 (+0.06), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), RIGL: 2.47 (+0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 11:45AM CST
JIVE: 5.34 (+0.02), JONE: 10.18 (+0.18), FXEN: 1.99 (+0.10), CDTI: 2.35 (+0.11), SGMO: 15.40 (+0.14), EVRY: 1.00 (-0.04), INXN: 32.04 (+0.14), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), BLDP: 2.66 (-0.26), PNTR: 7.90 (+0.01), PRSS: 2.95 (-0.08), BXE: 2.79 (+0.05), ANTH: 3.84 (+0.06), PIR: 12.52 (+0.17), PSTR: 4.63 (+0.14), MKTO: 28.24 (+0.20), ANDE: 45.11 (+0.71), DGLY: 11.50 (-0.40), DCTH: 1.14 (+0.04)
Strength Seen in Anthera (ANTH): Stock Soars 25% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:25AM CST
Anthera (ANTH) was a big mover last session, with shares surging 25% on the day.
ANTH: 3.84 (+0.06), AFFX: 11.45 (+0.02)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HNNA: 24.40 (+0.40), OFED: 20.41 (+0.16), DLHC: 2.21 (-0.06), BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), BIOC: 1.41 (+0.22), NWFL: 30.00 (+0.25), ATOS: 1.67 (+0.11), SPDC: 1.18 (+0.05), FSC: 7.23 (+0.12), OVBC: 24.00 (unch), QTWW: 2.96 (-0.04), ANTH: 3.84 (+0.06), IMI: 1.70 (-0.20), FBMS: 14.69 (+0.31), EXA: 10.46 (+0.09), FNJN: 2.77 (-0.36)
Most active Nasdaq-traded stocks
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.86 (-0.22), MU: 31.85 (-0.09), FTR: 8.38 (+0.01), AMD: 3.15 (+0.03), ANTH: 3.84 (+0.06), ACHN: 10.89 (-0.20), ODP: 9.59 (-0.02), MSFT: 43.87 (+0.78), INTC: 34.36 (+0.23), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03)
Anthera Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
PR Newswire - Tue Feb 10, 2:56PM CST
Anthera Pharmaceuticals (NASDAQ: ANTH) today announced that the company has received formal notification from the Nasdaq Stock Market ("Nasdaq"
, indicating that the Company has regained compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,000,000 in stockholders' equity or maintaining a market value of $50,000,000 or greater for ten consecutive business days. Nasdaq has determined that Anthera has maintained market value of at least $50,000,000 for the last ten consecutive business days and as such, the Company has met alternative listing requirements for continued listing. ANTH: 3.84 (+0.06)
Anthera Pharma spikes 30% on continuation of lupus study
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 10:41AM CST
ANTH: 3.84 (+0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus
PR Newswire - Tue Feb 10, 7:45AM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 study, evaluating the SRI-6 response at the 24 week time point. Enrollment in the trial is projected to conclude in mid-2015.
ANTH: 3.84 (+0.06)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
AYI: 163.40 (+0.78), BDC: 87.78 (+0.61), ANTH: 3.84 (+0.06), CB: 102.06 (+0.43), CGI: 25.30 (+0.05)
Anthera Pharmaceuticals names Klara A. Dickinson as SVP
M2 - Thu Jan 08, 4:54AM CST
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) disclosed on Wednesday the election of Klara A. Dickinson as senior vice president & chief regulatory officer.
ANTH: 3.84 (+0.06)
Anthera Pharmaceuticals Announces Appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer
PR Newswire - Wed Jan 07, 2:45PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced the appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer.
ANTH: 3.84 (+0.06)
Can the Uptrend Continue for Anthera Pharmaceuticals (ANTH)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 7:44AM CST
Can the Uptrend Continue for Anthera Pharmaceuticals (ANTH)?
ANTH: 3.84 (+0.06)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:35PM CST
CERS: 5.53 (+0.08), RICE: 19.13 (-0.22), ECR: 7.29 (+0.12), ANTH: 3.84 (+0.06), NERV: 4.68 (+0.09), AU: 12.33 (+0.36), JNUG: 30.90 (+1.14), WTI: 6.55 (+0.41), CYBX: 57.03 (+0.26), GST: 2.89 (unch)
Anthera jumps as interest in lupus med builds
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:36AM CST
ANTH: 3.84 (+0.06)
Anthera Pharmaceuticals Announces Lupus Symposium During 2015 JP Morgan Healthcare Conference
PR Newswire - Tue Dec 30, 1:30PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it is inviting its shareholders and investors to a symposium on Systemic Lupus Erythematosus (SLE) at 3:30 PM on Wednesday, January 14th at the Mystic Hotel in San Francisco, CA.
ANTH: 3.84 (+0.06)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jbcb9/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Boehringer Ingelheim - Amgen - GlaxoSmithKline - Merck & Co - Symphogen - Eisai - Rigel Pharmaceuticals - Immunomedics - HanAll Biopharma - PhytoHealth - Anthera Pharmaceuticals - SuppreMol - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/3jbcb9/idiopathic
IMMU: 3.84 (unch), ANTH: 3.84 (+0.06), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), RIGL: 2.47 (+0.05)
